Severe skin reaction secondary to concomitant radiotherapy plus cetuximab

The therapeutic use of monoclonal antibodies against the epidermal growth factor receptor (EGFR) is specifically associated with dermatologic reactions of variable severity. Recent evidence suggests superiority of the EGFR inhibitor (EGFRI) cetuximab plus radiotherapy compared to radiotherapy alone...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Bernhard, Belka, Claus
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2248588/
https://www.ncbi.nlm.nih.gov/pubmed/18226196
http://dx.doi.org/10.1186/1748-717X-3-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2248588/
https://www.ncbi.nlm.nih.gov/pubmed/18226196
http://dx.doi.org/10.1186/1748-717X-3-5

Ejemplares similares